ADMA Biologics (NASDAQ:ADMA) Posts Earnings Results, Beats Estimates By $0.04 EPS

ADMA Biologics (NASDAQ:ADMA) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04, Yahoo Finance reports. The company had revenue of $7.22 million during the quarter, compared to the consensus estimate of $5.71 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.

NASDAQ ADMA opened at $4.31 on Friday. The stock’s 50 day moving average is $4.59 and its 200 day moving average is $4.26. The company has a current ratio of 10.26, a quick ratio of 7.93 and a debt-to-equity ratio of 1.79. ADMA Biologics has a 12 month low of $2.08 and a 12 month high of $6.31. The stock has a market cap of $304.89 million, a PE ratio of -2.97 and a beta of 2.70.

ADMA has been the subject of a number of recent research reports. BidaskClub upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Wednesday. Dawson James downgraded ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research note on Monday, August 12th. Maxim Group set a $12.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $10.20.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: Which market index is the best?

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.